BRAF and melanoma: Since Src kinases function together with FAK, we hypothesized that co-targeting BRAF/MEK and FAK with avutometinib (RAF/MEK clamp) plus defactinib (FAKi) would show activity against Rac1-driven drug-resistant melanoma cells.